PhD, West Virginia University, Morgantown, WV
PharmD, The University of the Sciences in Philadelphia, Philadelphia, PA
Dr. Myers is an Associate Professor of Pharmacology in the Department of Diagnostic and Biomedical Sciences at The University of Texas, School of Dentistry – Houston. He received his Doctorate in Pharmacy (PharmD) from the University of the Sciences in Philadelphia in 1999, and Doctorate in Philosophy (PhD) from West Virginia University in 2005. Dr. Myers completed post-doctorate training in Pharmacokinetics and Pharmacodynamics at the University of Maryland, School of Pharmacy in 2007. Prior to joining the UT School of Dentistry – Houston he practiced as a Clinical Pharmacy Research Specialist at The University of Texas, M.D. Anderson Cancer Center for many years.
Dr. Myers has numerous research interests spanning the fields of basic and clinical sciences, including pharmacokinetics, pharmacodynamics, pharmacogenetics, bioanalytical method development and drug stability. Several of his research activities at UT School of Dentistry – Houston involve collaborations with clinical trials at M.D. Anderson Cancer Center. He is interested in determining if the pharmacokinetic levels of varenicline (Chantix), a drug approved by the FDA to assist in smoking cessation, are correlated to its pharmacodynamics ( treatment outcomes), primarily successful cessation.
While at M.D. Anderson Cancer Center, one of his many roles of was to apply clinical pharmacokinetics in adjusting real-time doses of busulfan (IV Busulvex), a drug used in patients prior to hematopoietic stem cell transplantation. In the research laboratory, Dr. Myers is engrossed in discovering novel metabolic pathways of busulfan, novel co-interacting medications, and determining the role of a dehydroalanine metabolite of busulfan in cellular toxicity – a possible new metabolic mechanism for busulfan injury.
Dr. Myers has a passion for applying pharmacogenetics (“personalized medicine”) into daily medical practice. As a member of the Clinical Pharmacogenetics and Implementation Consortium (CPIC), he is working with a group of genetic experts to develop practical clinical guidelines to inform clinicians with dosing of efavirenz (Sustiva), a drug used in the treatment of HIV infection, based on individual patient CYP2B6 phenotype. He is also heavily involved in a clinical trial at M.D. Anderson Cancer Center attempting to determine the influence of uridine 5'-diphospho-glucuronosyltransferase (UGT) pharmacogenetics on the pharmacokinetics and analgesic activity of hydromorphone in critical care settings.
Another facet of Dr. Myers’ research involves studying unknown hepatic toxification pathways of oral carcinogens found in natural substances, such as within Chinese herbal medicines, Betel Quid (“paan”) and Areca-Nut. Finally, Dr. Myers has collaborations with Clear River Enviro LLC in validating a desk-top machine (RxDestruct) that destroys pharmaceutical waste at the molecular level, allowing easy and safe disposal.